Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein.
about
Identifying Recent HIV Infections: From Serological Assays to GenomicsInter-laboratory assessment of a prototype multiplex kit for determination of recent HIV-1 infectionDetection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studiesPerformance characteristics of an antibody-based multiplex kit for determining recent HIV-1 infection.Improved testing of recent HIV-1 infections with the BioRad avidity assay compared to the limiting antigen avidity assay and BED Capture enzyme immunoassay: evaluation using reference sample panels from the German Seroconverter CohortDual testing algorithm of BED-CEIA and AxSYM Avidity Index assays performs best in identifying recent HIV infection in a sample of Rwandan sex workersSurveillance of recent HIV infections among newly diagnosed HIV cases in Germany between 2008 and 2014Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assayMore and better information to tackle HIV epidemics: towards improved HIV incidence assays.Evaluation of dried blood spots with a multiplex assay for measuring recent HIV-1 infectionEvaluation of a multiplex assay for estimation of HIV-1 incidence.Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward.Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypesComparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D.A comprehensive evaluation of the proficiency testing program for the HIV-1 BED incidence assayWhat Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?How can we better identify early HIV infections?Identifying Risk Factors for Recent HIV Infection in Kenya Using a Recent Infection Testing Algorithm: Results from a Nationally Representative Population-Based SurveyPerformance of Bio-Rad and Limiting Antigen Avidity Assays in Detecting Recent HIV Infections Using the Quebec Primary HIV-1 Infection Cohort.HIV Incidence Estimates Using the Limiting Antigen Avidity EIA Assay at Testing Sites in Kiev City, Ukraine: 2013-2014.Development of a New Limiting-Antigen Avidity Dot Immuno-Gold Filtration Assay for HIV-1 IncidenceExtensive Genetic Diversity of HIV-1 in Incident and Prevalent Infections among Malaysian Blood Donors: Multiple Introductions of HIV-1 Genotypes from Highly Prevalent Countries.Characterization of Humoral Immune Responses against Capsid Protein p24 and Transmembrane Glycoprotein gp41 of Human Immunodeficiency Virus Type 1 in China.Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma.Current and future assays for identifying recent HIV infections at the population levelCross-sectional HIV incidence estimation in HIV prevention research.Evaluation of the false recent classification rates of multiassay algorithms in estimating HIV type 1 subtype C incidence.Non-neutralizing antibodies in prevention of HIV infection.How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay.Strengthening HIV surveillance: measurements to track the epidemic in real time.Estimating False-Recent Classification for the Limiting-Antigen Avidity EIA and BED-Capture Enzyme Immunoassay in Vietnam: Implications for HIV-1 Incidence Estimates.Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.Weak HIV Antibody Responses in Perinatally-Infected Young Adults.HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication.Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection.Evaluation of the limiting antigen avidity EIA (LAg) in people who inject drugs in Greece.Measles virus IgG avidity assay for use in classification of measles vaccine failure in measles elimination settings.HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
P2860
Q26778001-7B395E71-9EFB-4E75-9724-F17715F40145Q28534491-4E1C837F-F0DE-4390-967D-FDB4A5E47318Q28730904-2674B3F4-B016-408A-A9AA-5D08F267DFA9Q33637675-66BC6301-E912-4716-9CB2-C121160C831DQ33706522-CEC11037-E611-44DE-B006-09C962A499CDQ33885838-0A028BE1-841C-45D1-9C9F-87D76D4B1ECCQ33892444-735487DC-2F33-499F-BB80-1D49C2A51677Q33916829-5E304589-5340-4714-8C1A-EF8A6A484B94Q33951907-EAE64E67-4A6B-4B04-B694-6798D5DDC387Q34214893-CF3A7ADD-193D-4585-A2EA-EB165AEEC069Q34745421-51BE7564-7448-47CA-AA74-53DE6F3FCE7CQ35080053-5B09649A-7FA4-4573-BDE3-AEC0C39B07EDQ35088760-396FADD4-8BF4-46A4-AED8-7E3E8243DAECQ35119643-1C77F36E-D432-487E-9447-38F0A89ECE5CQ35230246-8BF71132-090F-4203-8EC7-09AE49542477Q35273371-6E9EDB48-97A9-48BF-B33B-ACA3AE9FF92CQ35641144-1285DA3A-972D-43CA-9331-46EF3524D587Q35814304-67852137-5646-4BA4-870C-1D4F4AAC66D9Q36022269-68B830E1-DC5C-4ECC-AA64-6A1BC0DAE66CQ36029177-E9CC2438-3611-4140-8A81-984DA6632BE1Q36045124-B8A09EBA-0D84-4D9E-8FAA-1A08FB866678Q36101267-937D0C77-F2AF-44D9-87F7-45943A443009Q36117011-F3A2DDCA-8204-4D0E-8826-858451ECFD0FQ36179451-C7102235-0665-4FA5-B6FA-802A6C4FB57BQ36288430-1E49331A-F1D6-4803-BD13-0EA23CA918A1Q36516631-B8F71096-0267-40B4-9A5D-50CD0DC059EFQ37080530-A75764AF-6F4E-4CF0-88A9-2D7C9D606851Q37460164-3F222830-1DF4-4142-86CD-49F242564151Q38058120-B322E284-7E96-4C4A-BF07-430641512031Q38618790-3B69F766-40D6-4329-8A2F-84BFAD55652EQ38649701-4D442345-8D23-458E-A871-12FAE9C62CC6Q38843374-FFE86629-7237-46FD-A9EE-BEECF10FC4C6Q38963716-E8CA8BF7-98EB-430F-8AA0-57BB26EA9612Q40114912-F46D05CC-2610-4DA4-979E-F4EA83F5C9D8Q40145384-F6A3A251-475A-4CFB-861A-47D73097E498Q40203692-13C9E0DD-76C8-443F-8BD0-1E7F1748385DQ40440245-418AA36E-074B-4520-8DF0-6CAED6A1A07BQ40485453-FAC89078-C6C1-44CB-BA3F-EC55FBF814E4Q41427019-D029B1A2-479E-4DB9-B4F8-01AA21F70117Q41918753-564D8083-1A29-409C-924C-703D62E500E1
P2860
Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Development of two avidity-bas ...... type gp41 recombinant protein.
@en
Development of two avidity-bas ...... type gp41 recombinant protein.
@nl
type
label
Development of two avidity-bas ...... type gp41 recombinant protein.
@en
Development of two avidity-bas ...... type gp41 recombinant protein.
@nl
prefLabel
Development of two avidity-bas ...... type gp41 recombinant protein.
@en
Development of two avidity-bas ...... type gp41 recombinant protein.
@nl
P2093
P356
P1476
Development of two avidity-bas ...... type gp41 recombinant protein.
@en
P2093
Bharat S Parekh
Debra Kuehl
John N Nkengasong
Trudy Dobbs
Xierong Wei
P356
10.1089/AID.2009.0133
P577
2010-01-01T00:00:00Z